EMA Approval Submission for Teclistamab Multiple Myeloma Monotherapy
Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency (EMA) seeking approval for TECVAYLI® (teclistamab) monotherapy in adult patients with relapsed/refractory multiple myeloma (RRMM) after at least one prior therapy. This teclistamab multiple myeloma regulatory filing draws on Phase 3 MajesTEC-9 trial data, showing teclistamab’s superiority over standard regimens with a 71% reduction in progression or death risk (HR 0.29; 95% CI 0.23-0.38) and 40% lower mortality risk (HR 0.60; 95% CI 0.43-0.83) in patients mostly refractory to anti-CD38 antibodies and lenalidomide. It aims to establish teclistamab multiple myeloma therapy as a potential second-line standard, tackling unmet needs in relapsed patients with few options.
MajesTEC-9 Delivers PFS and OS Wins
The MajesTEC-9 trial highlights teclistamab multiple myelomas transformative edge in earlier-line RRMM, outperforming pomalidomide, bortezomib, and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd) on progression-free survival (PFS) and overall survival (OS). Among 614 patients with 1-3 prior lines—85% refractory to anti-CD38 therapies and 79% to lenalidomide, over 90% to their last regimen—teclistamab cut progression or death risk by 71%. An Independent Data Monitoring Committee recommended early unblinding. These findings extend teclistamab’s profile, approved in Europe in 2022 for three-plus prior lines and 2023 for reduced dosing (1.5 mg/kg biweekly post-complete response), as a bispecific T-cell engager hitting BCMA and CD3.
Phase 3 Rigor Backs Safety and Endpoints
MajesTEC-9 (NCT05572515), an ongoing randomized Phase 3 trial, pitted subcutaneous teclistamab against PVd or Kd in RRMM after 1-3 lines, requiring prior anti-CD38 and lenalidomide. Primary endpoints: PFS and cytokine release syndrome (CRS) severity. Secondaries included complete response or better (≥CR), response duration, time to next therapy, PFS2, OS, adverse events, and quality of life via EORTC QLQ-C30. Safety matched prior data—manageable, no new signals—with infections handled via monitoring, immunoglobulins, and prophylaxis. This design validates claims in a refractory group where relapses speed up and remissions fade.
HEOR and Access Boost from Bispecific Shift
Second-line teclistamab multiple myeloma approval could transform health economics, positioning bispecifics earlier to prolong PFS and OS, cut escalation costs in a disease hitting 35,000+ new EU cases yearly (22,700 deaths in 2022). The 71% PFS and 40% OS gains versus PVd/Kd boost cost-effectiveness for BCMA therapies in refractory patients lacking community options. Payers may benchmark against triplets, weighing CRS protocols, subcutaneous ease, and sustained responses versus CAR-T complexity—favoring off-the-shelf immunotherapy in relapses.
